Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Meredith, Ruby F ^a,c   Khazaeli, M B ^a   Macey, Daniel J ^a   Grizzle, William E ^a   Mayo, Matthew ^a,d   Schlom, Jeffrey ^b   Russell, Charles D ^a   LoBuglio, Albert F ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c The University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; IODINE 131; LEVOTHYROXINE SODIUM; MONOCLONAL ANTIBODY CC49; POTASSIUM IODIDE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ALPHA2B INTERFERON; VINBLASTINE;

ADULT; AGED; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MALE; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

AGED; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; GLYCOPROTEINS; HUMANS; INTERFERON-ALPHA; IODINE RADIOISOTOPES; MALE; MICE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 0032722426     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Crawford, E., Eisenberger, M., McLeod, D., Spaulding, J., Benson, R., Dorr, F., Blumenstein, B., Davis, M., and Goodman, P. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321: 419-424, 1989; Erratum: N. Engl. J. Med., 321: 1420, 1989.
2. Meredith, R., Bueschen, A., Khazaeli, M., Plott, W., Grizzle, W., Wheeler, R., Schlom, J., Russell, C., and LoBuglio, A. Treatment of metastatic prostate cancer with radiolabeled antibody CC49. J. Nucl. Med., 35: 1017-1022, 1994.
3. Schlom, J., Hand, P., Greiner, J., Colcher, D., Shrivastav, S., Carrasquillo, J., Reynolds, J., Larson, S., and Raubitschek, A. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res., 50 (Suppl. 3): 820s-827s, 1990.
4. Greiner, J., Smalley, R., Borden, E., Martin, E., Guadagni, F., Roselli, M., and Schlom, J. Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas. J. Surg. Oncol., 2 (Suppl.): 9-13, 1991.
5. Murray, J., Macey, D., Grant, E., Rosenblum, M., Kasi, L., Zhang, H., Katz, R., Riger, P., LeBherz, D., Bhadkamkar, V., Greiner, J., Schlom, J., and Podoloff, D. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following α-interferon Treatment. Cancer Res. (Suppl.), 55: 5925s-5928s, 1995.
6. 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin. Cancer Res., 6: 643-651, 1998.
7. Roselli, M., Guadagni, F., Buonomo, O., Belardi, A., Vittorini, V., Mariani-Costantini, R., Greiner, J., Casciani, C., and Schlom, J. Systemic administration of recombinant interferon α in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J. Clin. Oncol., 14: 2031-2042, 1996.
8. Myers, R., Meredith, R., Schlom, J., LoBuglio, A., Bueschen, A., Wheeler, R., Stockard, C., and Grizzle, W. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J. Urol., 152: 243-246, 1994.
9. Meredith, R., LoBuglio, A., Plott, W., Orr, R., Brezovich, I., Russell, C., Harvey, E., Yester, M., Wagner, A., Spencer, S., Wheeler, R., Saleh, M., Rogers, K., Polansky, A., Salter, M., and Khazaeli, M. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgGl,κ 17-1A monoclonal antibody. J. Nucl. Med., 32: 1162-1168, 1991.
10. 131I-labeled monoclonal antibody therapy in patients with metastatic colorectal cancer. Clin. Caner Res., 2: 1811-1818, 1996.
11. Loevinger, R., and Berma, M. Revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No. 1, Society of Nuclear Medicine, New York, 1976.
12. Snyder, W., Ford, M., Warner, G., and Watson, S. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11, Society of Nuclear Medicine, New York, 1975.
13. Muraro, R., Wunderlich, D., Thor, A., Lundy, J., Noguchi, P., Cunningham, R., and Schlom, J. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res., 45: 5769-5780, 1985.
14. LoBuglio, A., Wheeler, T., Trang, J., Haynes, A., Rogers, K., Harvey, E., Sun, L., Ghrayeb, J., and Khazaeli, M. Mouse/human chimeric monoclonal antibody in man. Kinetics and immune response. Proc. Natl. Acad. Sci. USA, 86: 4220-4224, 1989.
15. Labaune, J. Handbook of Pharmacokinetics: Toxicity Assessment of Chemicals. New York: John Wiley & Sons, 1989.
16. Snedecor, G., and Cochran, W. Statistical Methods, Ed. 7, pp. 191-193. Ames, Iowa: The Iowa State University Press, 1980.
17. 131I-chimeric B72.3 antibody therapy. Antibody Immunoconjug. Radiopharm. 6: 39-46, 1993.